Anti-H7N9 whole human monoclonal antibody 5G22, and preparation method and application thereof

A monoclonal antibody, fully human technology, applied in the field of immunology, can solve the problems of rimantadine drug resistance and no effective treatment methods, and achieve the goal of reducing cumbersome operations and costs, high affinity and specificity, and low production costs Effect
CN109957010AActive Publication Date: 2019-07-02SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI
4 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI
Publication Date
2019-07-02

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention relates to an anti-H7N9 whole human monoclonal antibody 5G22, and a preparation method and an application thereof, the anti-H7N9 whole human monoclonal antibody 5G22 or a biologically active fragment derived from the monoclonal antibody and capable of specifically binding H7N9. The antibody has a heavy chain variable region and a light chain variable region. The heavy chain variable region and light chain variable region respectilvey have 3 complementarity determining regions (CDRs). The antibody 5G22 is capable of specifically binding, detecting and neutralizing H7N9 viruses, and more suitable and more promising as a macromolecular drug for treating influenza viruses.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to an anti-H7N9 fully human monoclonal antibody and its preparation method and application, in particular to the anti-H7N9 fully human monoclonal antibody 5G22 and its preparation method and application, belonging to the technical field of immunology. Background technique

[0002] Among the top ten best-selling drugs in the world in 2015, six are fully human or humanized monoclonal antibody drugs. Ranked first is AbbVie's anti-TNFa monoclonal antibody Humira for the treatment of arthritis. This is a fully human monoclonal antibody and has been the king of drugs with sales of more than 10 billion for three consecutive years. Since the first monoclonal antibody drug was launched in 1986, monoclonal antibody drugs have experienced mouse monoclonal antibody drugs (Orthoclone OKT3), chimeric monoclonal antibody drugs (Rituximab), humanized monoclonal antibody drugs (Herceptin) and fully human monoclonal antibody drugs. Monoclonal anti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More